India Pharma Outlook Team | Tuesday, 10 March 2026
Bristol Myers Squibb said its experimental therapy improved patient outcomes in a late-stage blood cancer trial, offering new hope for people living with advanced multiple myeloma.
The company announced that its investigational drug mezigdomide, when used in combination with other treatments, significantly improved progression-free survival in patients whose disease had returned or stopped responding to earlier therapies.
The results come from a Phase 3 study known as SUCCESSOR-2, which tested mezigdomide alongside carfilzomib and dexamethasone. According to the company, the combination helped patients live longer without their cancer worsening compared with those receiving the standard regimen alone. The improvement met the study’s primary goal and showed a statistically significant benefit for patients with relapsed or refractory multiple myeloma.
Also Read: Advancing Interventional Radiology in India Through Collaboration
Researchers said the findings highlight the potential of mezigdomide, an oral therapy designed to harness the body’s immune system to fight cancer cells. The drug belongs to a newer class of medicines known as CELMoDs, which target a protein called cereblon to trigger the destruction of malignant cells.
The company noted that the safety profile seen in the late-stage blood cancer trial was consistent with earlier studies. While some side effects were observed, the overall results supported continued development of the therapy. Detailed findings from the trial are expected to be presented at an upcoming medical meeting and shared with health regulators.
Multiple myeloma remains one of the most challenging blood cancers to treat, especially after patients relapse following initial therapies. As the disease progresses, treatment options often become limited.
Bristol Myers Squibb plans to use the latest trial data to support future regulatory submissions, potentially moving mezigdomide closer to becoming a new treatment option for patients battling advanced multiple myeloma.
